Paradoxical Alzheimer's finding may provide better understanding of memory loss

Do you remember the seventh song that played on your radio on the way to work yesterday?

Most of us don't, thanks to a normal forgetting process that is constantly “cleaning house” – culling inconsequential information from our brains. Researchers at the Buck Institute now believe that this normal memory loss is hyper-activated in Alzheimer's disease (AD) and that this effect is key to the profound memory loss associated with the incurable neurodegenerative disorder.

Last year, this same group of researchers found that they could completely prevent Alzheimer's disease in mice genetically engineered with a human Alzheimer's gene—“Mouzheimer's”—by blocking a single site of cleavage of one molecule, called APP for amyloid precursor protein. Normally, this site on APP is attacked by molecular scissors called caspases, but blocking that process prevented the disease. Now they have studied human brain tissue and found that, just as expected, patients suffering from AD clearly show more of this cleavage process than people of the same age who do not have the disease. However, when they extended their studies to much younger people without Alzheimer's disease, they were astonished to find an apparent paradox: these younger people displayed as much as ten times the amount of the same cleavage event as the AD patients. The researchers now believe they know why.

The Buck Institute study implicates a biochemical “switch” associated with that cleavage of APP, causing AD brains to become stuck in the process of breaking memories, and points to AD as a syndrome affecting the plasticity or malleability of the brain. The study, due to be published in the March 7 issue of the Journal of Alzheimer's Disease, provides new insight into a molecular event resulting in decreased brain plasticity, a central feature of AD.

“Young brains operate like Ferraris – shifting between forward and reverse, making and breaking memories with a facility that surpasses that of older brains, which are less plastic,” said Dale Bredesen, MD, Buck Institute faculty member and leader of the research group. “We believe that in aging brains, AD occurs when the ‘molecular shifting switch' gets stuck in the reverse position, throwing the balance of making and breaking memories seriously off kilter.”

In previous research, lead author Veronica Galvan, PhD, prevented this cleavage in mice genetically engineered to develop the amyloid plaques and deposits associated with AD. These surprising mice had normal memories and showed no signs of brain shrinkage or nerve cell damage, despite the fact that their brains were loaded with the sticky A-beta plaques that are otherwise associated with Alzheimer's disease.

“A-beta is produced throughout the brain throughout life; we believe that it is a normal regulator of the synapses, the connections between neurons,” said Galvan, who added that AD, like cancer, is a disease in which imbalanced cell signaling plays an important role.

“The fact that many people develop A-beta plaques yet show no symptoms of AD tells us that the downstream signaling of A-beta—not just A-beta itself—is critical,” said Bredesen, “and these pathways can be targeted therapeutically. Simply put, we can restore the balance.” Continuing research at the Buck Institute focuses on nerve signaling and efforts to “disconnect” the molecular mechanism that throws memory-making in the reverse direction, as well as understanding mechanisms that support brain cell connections that are crucial to the process of memory making.

AD is an incurable neurodegenerative disease currently affecting 5.1 million Americans. AD results in dementia and memory loss, seriously affecting a person's ability to carry out activities of daily living. AD costs the U.S. $148 billion annually, in addition to untold family suffering.

Joining Bredesen and Galvan as co-authors of the paper, “C-terminal cleavage of the amyloid precursor protein at Asp664: a switch associated with Alzheimer's disease” are Surita Banwait, BA; Junli Zhang, MD; Olivia F. Gorostiza, Marina Ataie, BS; Wei Huang, BS; and Danielle Crippen, BA of the Buck Institute, as well as Edward H. Koo, MD, of the University of California, San Diego, Department of Neuroscience. The work was supported by the Joseph Drown Foundation, The National Institute on Aging, the Bechtel Foundation, and the Alzheimer's Association.

The Buck Institute is the only freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual's life. The National Institute of Aging designated the Buck a “Nathan Shock Center of Excellence in the Biology of Aging,” one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer's and Parkinson's disease, cancer and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For more information: www.buckinstitute.org.

The Journal of Alzheimer's Disease ( http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 3.058 according to Thomson Scientific Institute for Scientific Information's 2006 Journal Citation Reports.